A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy

Sekine I, Segawa Y, Kubota K and Saeki T: Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 104:711–717. 2013. View Article : Google Scholar : PubMed/NCBI

Richardson JL, Marks G and Levine A: The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol. 6:1746–1752. 1988.PubMed/NCBI

Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J, Palmer M, Zee B, Levy M and Pater J: Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 12:1050–1057. 1994.PubMed/NCBI

Yang LP and Scott LJ: Palonosetron: in the prevention of nausea and vomiting. Drugs. 69:2257–2278. 2009. View Article : Google Scholar : PubMed/NCBI

Curran MP and Robinson DM: Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs. 69:1853–1878. 2009. View Article : Google Scholar : PubMed/NCBI

MASCC antiemesis tool (MAT), . http://www.mascc.org/matAccessed. March 3–2010

NCCN Clinical Practice Guidelines in Oncology-Antiemesis- ver.4 2009. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportiveAccessed. March 3–2010

National Cancer Institute, . (2009) Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. Available from. https://wiki.nci.nih.gov/display/VKC/Common+Terminology+Criteria+for+Adverse+Events+FAQ#CommonTerminology Criteria for Adverse Events FAQ - What is the official reference citation for CTCAE v40. Accessed. May 29–2009

Aapro MS: Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag. 3:1009–1020. 2007.

Ioannidis JP, Hesketh PJ and Lau J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 18:3409–3422. 2000.PubMed/NCBI

Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J and Wilkinson JR: A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol. 7:945–952. 1996. View Article : Google Scholar : PubMed/NCBI

Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F and Macciocchi A: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 17:1441–1449. 2006. View Article : Google Scholar : PubMed/NCBI

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T and Mitsuhashi S: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial. Lancet Oncol. 10:115–124. 2009. View Article : Google Scholar : PubMed/NCBI

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A and Grunberg S99-04 Palonosetron Study Group: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 98:2473–2482. 2003. View Article : Google Scholar : PubMed/NCBI

Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A and Aapro M: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 14:1570–1577. 2003. View Article : Google Scholar : PubMed/NCBI

Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med. 358:2482–2494. 2008. View Article : Google Scholar : PubMed/NCBI

Hesketh PJ, Aapro M, Street JC and Carides AD: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 18:1171–1177. 2010. View Article : Google Scholar : PubMed/NCBI